Reply to K. Masuda et al

Dean A Fennell¹, Paul Taylor¹, David Gilligan¹+8

• ¹Dean A. Fennell, PhD, MD, University of Leicester and University Hospitals of Leicester National Health Service Trust, Leicester, United Kingdom; Paul Taylor, MD, Wythenshawe Hospital, Manchester, United Kingdom; David Gilligan, MD, Cambridge University Hospitals National Health Service Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom; Takashi Nakano, MD, PhD, Hyogo College of Medicine, Nishinomiya, Japan; Arnaud Scherpereel, MD, PhD, Calmette Hospital, Regional University Hospital of Lille, Lille, France; Nick Pavlakis, MD, PhD, Northern Cancer Institute, St Leonards, NSW, Australia; Jan P. van Meerbeeck, MD, PhD, Universitair Ziekenuis, Antwerp, Belgium; Joachim G.J.V. Aerts, MD, PhD, Erasmus Medical College, Rotterdam, the Netherlands; Anna K. Nowak, MD, PhD, University of Western Australia and Sir Charles Gairdner Hospital, Perth, WA, Australia; Hedy Kindler, MD, University of Chicago Medical Center, Chicago, IL; and Paul Baas, MD, PhD, Netherlands Cancer Institute, Amsterdam, the Netherlands.